Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: Results of a pilot study

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 359-366

  Freyer, Gilles ^a   Duret, Aude ^a   Milano, Gerard ^b   Chatelut, Etienne ^c   Rebischung, Christine ^d   Delord, Jean Pierre ^c   Merrouche, Yacine ^e   Lledo, Gerard ^f   Etienne, Marie Christine ^b   Falandry, Claire ^a  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e Institut de Cancerologie de la Loire   (France)

^f Clinique Saint Jean   (France)

Author keywords

Irinotecan; Metastatic colorectal cancer; Pharmacogenetics

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG MEGADOSE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHARMACOGENETICS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79851475207     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
2. Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004. (Pubitemid 41095110)
4. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004. (Pubitemid 41095086)
5. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G and Sparreboom A: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001.
6. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998. (Pubitemid 28096082)
7. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A andRatain MJ: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65: 576-582, 1999. (Pubitemid 29237332)
8. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47, 2002. (Pubitemid 34982202)
9. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE and Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382-1388, 2004. (Pubitemid 41103619)
10. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C and Boige V: High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology 74: 17-24, 2008.
11. Villafranca E, Okruzhnov Y, Dominguez MA, García-Foncillas J, Azinovic I, Martínez E, Illarramendi JJ, Arias F, Martínez Monge R, Salgado E, Angeletti S and Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19: 1779-1786, 2001. (Pubitemid 32230880)
12. Iacopetta B, Grieu F, Joseph D and Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827-830, 2001. (Pubitemid 33010548)
13. Marsh S, McKay JA, Cassidy J and McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19: 383-386, 2001.
14. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K and Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000. (Pubitemid 32059164)
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
16. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ and Ladner RD: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904, 2003. (Pubitemid 36667162)
17. Rouits E, Boisdron-Celle M, Morel A and Gamelin E: Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free Cortisol and 6β-hydroxycortisol in routine practice for CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake. J Chromatogr B Analyt Technol Biomed Life Sci 793: 357-366, 2003. (Pubitemid 37271976)
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
19. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Publish date: August 9, 2006. http://ctep.cancer.gov
20. International Conference on Harmonization Guidelines. http://www.ich.org.
21. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D and Georgoulias V: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798-805, 2006.
22. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M and Masi G; Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007. (Pubitemid 46797946)
23. Lee JC, Chow NH, Wang ST and Huang SM: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748-753, 2000.
24. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005.
25. Porebska I, Harlozinska A and Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 21: 105-115, 2000. (Pubitemid 30114656)
26. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208, 2004. (Pubitemid 41079832)
27. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
28. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K and Jackman AL: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 9: 792-801, 2003. (Pubitemid 36182617)
29. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S and Lenz HJ: Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17: 46-49, 2002. (Pubitemid 41398991)
30. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK and Seymour MT: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26: 2690-2698, 2008.
31. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E and Fountzilas G: Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan-containing adjuvant chemotherapy. BMC Cancer 9: 339, 2009.
32. Rhodes KE, Zhang W, Yang D, Press OA, Gordon M, Vallböhmer D, Schultheis AM, Lurje G, Ladner RD, Fazzone W, Iqbal S and Lenz HJ: ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett 21: 23-30, 2007.
33. McLeod HL and Watters JW: Irinotecan pharmacogenetics: Is it time to intervene? J Clin Oncol 22: 1356-1359, 2004.